ARDANA ANNOUNCES LAUNCH OF INVICORP™

IN DENMARK FOR ERECTILE DYSFUNCTION

Edinburgh, UK, 19 December 2006;  Ardana plc (LSE:ARA), announces today that Invicorp™ its injectable treatment for erectile dysfunction is now available for sale in Denmark.

Invicorp™ is a combination of phentolamine mesylate and vasoactive intestinal polypeptide and is delivered by self-administered penile injection for the treatment of moderate to severe erectile dysfunction.  Erectile dysfunction is male impotence resulting from an inability to have or maintain an erection sufficient for penetration during coitus.  It is estimated that 52 per cent of men over the age of 40 suffer at some time from erectile dysfunction and many of them are unsuitable for treatment with existing oral therapies (1).

Dr. Maureen Lindsay, Chief Executive of Ardana, said:

“We are delighted to announce the launch of Invicorp™in Denmark today our third marketed product in Europe and an important step in our programme for developing our portfolio.  Invicorp™represents a new injectable treatment option for patients who currently have limited non- oral therapies for this condition. “

The non oral erectile dysfunction market in the key European countries is estimated to be €31.3 million and is growing at 7% per annum (2).

(1).Feldman H.M., et al.  Journal of Urology 1994 Jan. 151(1): 54-61.

(2). IMS Health MAT February 2006.

For more information contact:

About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and marketing of innovative products to improve human reproductive health, a $25.5 billion market.

Since its foundation, Ardana has maintained a broad and balanced portfolio to manage risk and actively pursues product and technology in-licensing and outlicensing to maintain a robust pipeline.

Ardana’s lead products are summarised below:

• Emselex®, a once a day treatment for overactive bladder which Ardana has exclusive UK marketing and promotion rights and is being distributed in collaboration with Novartis UK Limited;
• Striant™ SR, a testosterone replacement therapy that has been launched by Ardana through its own sales force in the UK and through marketing partners in certain European countries, as a treatment for men with hypogonadism;
• Teverelix LA, in development for three initial indications (prostate cancer, BPH and endometriosis);
• Testosterone Cream, a trans dermal testosterone delivery system in development for the treatment of male hypogonadism, in Phase II trials;
• Invicorp™, an injectable combination drug treatment for erectile dysfunction, for which Ardana has marketing and manufacturing rights in Europe.
• EP01572 a growth hormone secretagogue in late stage development for the diagnosis of hormone deficiency 

In addition, Ardana has a strong portfolio of follow-on products in development.

Ardana is listed on the Main Market of the London Stock Exchange.

For further information please see www.ardana.co.uk

back to top